Septerna, Inc. (NASDAQ:SEPN) Given Average Recommendation of “Moderate Buy” by Brokerages

Septerna, Inc. (NASDAQ:SEPN) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $33.8333.

A number of brokerages recently commented on SEPN. Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright increased their target price on Septerna from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Truist Financial began coverage on shares of Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target on the stock. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd.

Insiders Place Their Bets

In other news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $5,046,834.73. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Septerna

Hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its position in Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after purchasing an additional 744 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Septerna in the fourth quarter worth approximately $35,000. Covestor Ltd increased its position in shares of Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC lifted its holdings in Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares in the last quarter.

Septerna Stock Down 4.2%

SEPN opened at $29.02 on Friday. The company has a market capitalization of $1.30 billion, a PE ratio of -19.22 and a beta of 3.85. The firm has a 50-day simple moving average of $26.95 and a two-hundred day simple moving average of $22.27. Septerna has a 52 week low of $4.66 and a 52 week high of $32.63.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.